Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ANTHOTCMKTS:AOLSOTCMKTS:AOXGOTCMKTS:ATRXOTCMKTS:PXYN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANTHAnthera Pharmaceuticals$0.00$0.00▼$0.00N/A1.82200 shsN/AAOLSAeolus Pharmaceuticals$0.00$0.00▼$0.01N/A1.2835 shs35 shsAOXGAoxing Pharmaceutical$0.01$0.01$0.00▼$0.02$2.86M6.738,169 shsN/AATRXAdhera Therapeutics$0.00$0.00▼$0.02N/A3.858 shsN/APXYNPraxsyn$0.00$0.00▼$0.00N/AN/AN/AN/A20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANTHAnthera Pharmaceuticals0.00%0.00%0.00%0.00%0.00%AOLSAeolus Pharmaceuticals0.00%0.00%0.00%0.00%0.00%AOXGAoxing Pharmaceutical0.00%0.00%-31.19%-6.25%+70.45%ATRXAdhera Therapeutics0.00%0.00%0.00%0.00%-99.05%PXYNPraxsyn0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANTHAnthera PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAOXGAoxing PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/AATRXAdhera TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APXYNPraxsynN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANTHAnthera Pharmaceuticals 0.00N/AN/AN/AAOLSAeolus Pharmaceuticals 0.00N/AN/AN/AAOXGAoxing Pharmaceutical 0.00N/AN/AN/AATRXAdhera Therapeutics 0.00N/AN/AN/APXYNPraxsyn 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANTHAnthera PharmaceuticalsN/AN/AN/AN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/AN/AN/AN/AN/AAOXGAoxing PharmaceuticalN/AN/AN/AN/AN/AN/AATRXAdhera TherapeuticsN/AN/AN/AN/AN/AN/APXYNPraxsynN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANTHAnthera PharmaceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/AAOXGAoxing PharmaceuticalN/AN/A0.00∞N/AN/AN/AN/AN/AATRXAdhera Therapeutics-$2.11MN/A0.00N/AN/AN/AN/AN/AN/APXYNPraxsynN/AN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANTHAnthera PharmaceuticalsN/AN/AN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/AN/AN/AN/AAOXGAoxing PharmaceuticalN/AN/AN/AN/AN/AATRXAdhera TherapeuticsN/AN/AN/AN/AN/APXYNPraxsynN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANTHAnthera PharmaceuticalsN/AAOLSAeolus PharmaceuticalsN/AAOXGAoxing PharmaceuticalN/AATRXAdhera TherapeuticsN/APXYNPraxsynN/AInsider OwnershipCompanyInsider OwnershipANTHAnthera Pharmaceuticals2.08%AOLSAeolus Pharmaceuticals66.60%AOXGAoxing Pharmaceutical17.80%ATRXAdhera Therapeutics28.20%PXYNPraxsynN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANTHAnthera Pharmaceuticals20N/AN/ANot OptionableAOLSAeolus Pharmaceuticals4N/AN/ANot OptionableAOXGAoxing Pharmaceutical350381.21 million313.35 millionNot OptionableATRXAdhera Therapeutics211.63 million8.35 millionNot OptionablePXYNPraxsyn66N/AN/ANot OptionableATRX, ANTH, AOLS, PXYN, and AOXG HeadlinesRecent News About These CompaniesPXYN.PK - Praxsyn Corp | Stock Price & Latest News | ReutersAugust 13, 2022 | reuters.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATRX, ANTH, AOLS, PXYN, and AOXG Company DescriptionsAnthera Pharmaceuticals OTCMKTS:ANTHAnthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.Aeolus Pharmaceuticals OTCMKTS:AOLSAeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.Aoxing Pharmaceutical OTCMKTS:AOXG$0.0075 0.00 (0.00%) As of 07/1/2025Aoxing Pharmaceutical Company, Inc. a specialty pharmaceutical company, engages in research and development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Republic of China. The company's principal products include Zhongtong'an, a capsule of herbal extraction for the indication of oral and dental pain; and Yiqi Qiangshen Granule, an OTC herbal extraction for tonifying qi and empowering body, and promoting blood circulation to remove meridian obstruction, as well as Tilidine hydrochloride, an orally-absorbed synthetic narcotic analgesic tablet used in 50mg or 100mg dosage for relief of acute, moderate to severe pain, and chronic cancer-related pain. Its products under development comprise Oxycodone and Acetaminophen tablets and capsules, which has completed clinical trials for the treatment of acute and chronic pain; Buprenorphine/Naloxone, a sublingual combo tablet that has completed Phase II clinical trials for the treatment of opioid dependence; and Tilidine/Naloxone, a compound capsule which is in Phase II clinical trial to treat acute and chronic pain. The company was formerly known as China Aoxing Pharmaceutical Company, Inc. and changed its name to Aoxing Pharmaceutical Company, Inc. in March 2010. Aoxing Pharmaceutical Company, Inc. is headquartered in Shijiazhuang, China.Adhera Therapeutics OTCMKTS:ATRXAdhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.Praxsyn OTCMKTS:PXYNPraxsyn Corporation, a health care company, provides medical practitioners with medications and services for their patients. It formulates non-narcotic and non-habit forming medications using therapeutic and preventative agents in the forms of transdermal creams, patches, and oral capsules for pain management, erectile dysfunction, and metabolic therapies. Praxsyn Corporation provides its products to patients covered under the California workers' compensation system, as well as preferred provider contracts. The company was formerly known as The PAWS Pet Company, Inc. and changed its name to Praxsyn Corporation in March 2014. Praxsyn Corporation was founded in 2005 and is headquartered in Las Vegas, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Jefferies Raises Broadcom Price Target to $315: 19% Upside Ahead Dan Ives’ Bold $5 Trillion Forecast for Microsoft Stock 3 Utility Stocks That Combine Income and Stability 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
